Ocrelizumab (Ocrevus)

Ocrevus (ocrelizumab) is covered only for FDA‑approved indications — treatment of adults (≥18) with relapsing forms of MS (including clinically isolated syndrome, relapsing‑remitting, and active secondary progressive) or primary progressive MS — and is excluded for non‑FDA indications and patients under 18. Coverage requires documentation of diagnosis and MS subtype, prescribing by or consultation with an MS specialist/neurologist, meeting applicable safety criteria, adherence to labeled IV dosing (initial two 300 mg infusions two weeks apart, then 600 mg every 6 months), and approvals are issued for 12 months.

"Ocrevus is indicated for the treatment of adult patients with relapsing or primary progressive forms of multiple sclerosis (MS)."

Sign up to see full coverage criteria, indications, and limitations.